Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry

By Olivares J. M.   Peuskens J.   Pecenak J.   Resseler S.   Jacobs A.   Akhras K. S.  

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2197-2206

Informa Healthcare

Access to resources Recommend Favorite

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries

By Peuskens J.   Olivares J.M.   Pecenak J.   Tuma I.   bij de Weg H.   Eriksson L.   Resseler S.   Akhras K.   Jacobs A.  

Current Medical Research and Opinion, Vol. 26, Iss. 3, 2010-03 ,pp. : 501-509

Informa Healthcare

Access to resources Recommend Favorite

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia

By Witte Michael M.   Case Michael G.   Schuh Kory J.   Ascher-Svanum Haya  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 315-323

Informa Healthcare

Access to resources Recommend Favorite

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

By Willis Michael   Svensson Marianne   Löthgren Mickael   Eriksson Bo   Berntsson Anders   Persson Ulf  

The European Journal of Health Economics, Vol. 11, Iss. 6, 2010-12 ,pp. : 585-594

Springer Publishing Company

Access to resources Recommend Favorite

Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report

By  

Current Drug Safety, Vol. 7, Iss. 1, 2012-02 ,pp. : 21-23

Bentham Science Publishers

Access to resources Recommend Favorite